Background The cardiovascular safety of celecoxib, as compared with nonselective nonsteroidal
antiinflammatory drugs (NSAIDs), remains uncertain. Methods Patients who required …

Background Cyclo-oxygenase (COX)-2-selective non-steroidal anti-inflammatory drugs (NSAIDs)
and non-selective NSAIDs plus a proton-pump inhibitor (PPI) have similar upper …

Monoclonal antibodies to CDS have been shown to activate T cells in vivo and in vitro but
have also been shown to render T cells anergic in vitro. In this study G4. 18, a mouse IgG3 …

… Chunming Li and Manuela Berger are full-time employees of Pfizer and own stocks and
shares in Pfizer. Lee S. Simon has served as a consultant for Pfizer, Astra-Zeneca, PLx Pharma, …

Objective. Nonsteroidal antiinflammatory drugs (NSAID) not only cause damage to the upper
gastrointestinal (GI) tract but also affect the lower GI tract. To date, there is no endpoint that …

Objective To determine the relative risks of cardiovascular ( CV ), gastrointestinal ( GI ), and
renal adverse events during long‐term treatment with celecoxib, compared with ibuprofen …

Objective. To evaluate the analgesic efficacy of high-dose celecoxib in the treatment of
moderate to extreme pain and inflammation associated with acute gouty arthritis. Methods. A …

Objective: Further understand the safety profile of celecoxib and provide safety information for
important adverse events (AEs). Methods: Analysis of randomized controlled trials from the …

PURPOSE To determine whether p53 protein expression is similar within primary colorectal
cancer (CRC) and synchronous regional and distant metastases and to assess whether p53 …

Objective To evaluate the efficacy and safety of celecoxib versus placebo in the prevention
and treatment of colorectal polyposis in children with familial adenomatous polyposis (FAP). …